Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroscience
Biotech
Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D
Ipsen has landed the chance to option two candidates that could benefit from its “neuroscience expertise in movement disorders.”
Nick Paul Taylor
Apr 22, 2024 7:01am
Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
Mar 25, 2024 8:16am
Seelos' sugar therapy fails to improve ALS severity in ph. 2/3
Mar 19, 2024 10:00am
Neuropsych biotech Engrail closes $157M series B
Mar 19, 2024 8:00am
Alto aims for $101M IPO to pave neuro development climb
Jan 30, 2024 11:37am
J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy
Jan 23, 2024 10:54am